Home > Boards > US Listed > Biotechs > ImmunoGen, Inc. (IMGN)

Sounds good..

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 321
Posts 41,088
Boards Moderated 34
Alias Born 09/20/01
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/25/2020 8:39:43 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/25/2020 8:39:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/25/2020 8:38:30 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/25/2020 8:38:05 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/25/2020 8:37:34 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2020 5:20:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:54:02 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 12:40:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2020 6:38:07 AM
ImmunoGen Reports Recent Progress and 2019 Financial Results Business Wire - 2/14/2020 6:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2020 2:59:40 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2020 3:04:36 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 7:53:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:28:30 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:28:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:27:09 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:26:34 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:25:29 AM
Schedule 13g Edgar (US Regulatory) - 2/10/2020 9:11:28 AM
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire - 2/6/2020 4:30:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 11:50:20 AM
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 2/3/2020 4:30:00 PM
ImmunoGen Announces Conference Call to Discuss Its 2019 Operating Results Business Wire - 1/30/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/27/2020 4:13:56 PM
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire - 1/27/2020 4:01:00 PM
XenaLives Member Level  Friday, 08/02/19 07:50:58 AM
Re: None
Post # of 667 
Sounds good..

Quote:

FINANCIAL GUIDANCE

Following the completion of its operational review in June 2019, ImmunoGen has updated its financial guidance for 2019 as follows:

- revenues between $40 million and $45 million;
- operating expenses between $175 million and $180 million; and
- cash and cash equivalents at December 31, 2019, between $165 million and $170 million.

ImmunoGen expects that its current cash, together with expense reductions resulting from the operational changes previously announced and anticipated cash receipts from partners, will fund operations through the release of top-line results from the upcoming mirvetuximab Phase 3 study in platinum-resistant ovarian cancer, which are expected in the first half of 2022.




https://finance.yahoo.com/news/immunogen-reports-recent-progress-second-103000972.html?.tsrc=rss



In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist